ArticleThe American journal of tropical medicine and hygiene2025
Diagnostic Yield of Strongyloides stercoralis Screening in Immunocompromised Patients and Those with Anticipated Immunocompromise in a Dutch Tertiary Hospital: A Retrospective Cohort Study.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Strongyloidiasis Beyond the Tropics: Updated Epidemiological Evidence from a Historically Endemic Region in Spain.Tropical medicine and infectious disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strongyloidiasis is a parasitic infection caused by the intestinal helminth Strongyloides stercoralis (S. stercoralis). It is prevalent in tropical and subtropical regions but increasingly diagnosed in nonendemic countries because of migration and travel. In immunocompromised patients, infection with S. stercoralis can lead to a potentially lethal hyperinfection syndrome. Consequently, several guidelines recommend screening immunocompromised patients for S. stercoralis IgG. We aimed to assess the yield of this screening in our tertiary hospital in the Netherlands, a nonendemic country. We performed a retrospective cohort study, in which we identified all immunocompromised patients and those expected to be immunocompromised who were tested for S. stercoralis IgG between January 2010 and April 2022. For these patients, we collected demographic and clinically relevant data from electronic patient files. Strongyloides stercoralis IgG test results were positive in 17/379 patients (4.5%), all of whom were born in an endemic country. Eosinophilia was present in 7/17 patients (41.2%). Over the years, the number of diagnostic tests performed for S. stercoralis IgG has increased significantly, but the number of positive test results per year has not. Focusing screening on patients who have lived in endemic regions and less on travelers will improve diagnostic yield. We recommend screening all immunocompromised patients from high-endemic countries and highly immunocompromised patients with relevant travel history. For less severely immunocompromised patients, screening should be individualized based on travel characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.